Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Share-based Compensation for 7 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 4.74% to $14.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $59.9 million, a 8.89% increase, with the full-year FY2025 number at $59.9 million, up 8.89% from a year prior.
  • Share-based Compensation was $14.5 million for Q4 2025 at Kymera Therapeutics, down from $15.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $15.8 million in Q3 2025 to a low of -$16.0 million in Q4 2021.
  • A 5-year average of $9.7 million and a median of $11.0 million in 2023 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 762.35% in 2021; the steepest drop was 975.42% in 2021.
  • Kymera Therapeutics' Share-based Compensation stood at -$16.0 million in 2021, then soared by 155.7% to $8.9 million in 2022, then rose by 22.33% to $10.9 million in 2023, then rose by 26.62% to $13.8 million in 2024, then grew by 4.74% to $14.5 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Share-based Compensation are $14.5 million (Q4 2025), $15.8 million (Q3 2025), and $15.4 million (Q2 2025).